Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qomel CoSAU:9600 +2.13%23 Return-on-Tangible-Equity is 8.33% as of Dec. 2025, which is 71% below its 10-year median of 29.21. GuruFocus rates SAU:9600 with a GF Score™ of 23/100. The stock has 3 warning signs investors should review. Among 576 Healthcare Providers & Services companies, Qomel Co ranks better than 56.25% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Qomel Co's annualized net income for the quarter that ended in Dec. 2025 was ﷼9.8 Mil. Qomel Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was ﷼117.4 Mil. Therefore, Qomel Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 8.33%.
The historical rank and industry rank for Qomel Co's Return-on-Tangible-Equity or its related term are showing as below:
SAU:9600'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 13.21 Med: 29.21 Max: 38.72
Current: 13.21
During the past 3 years, Qomel Co's highest Return-on-Tangible-Equity was 38.72%. The lowest was 13.21%. And the median was 29.21%.
SAU:9600's Return-on-Tangible-Equity is ranked better than 56.25% of 576
companies
in the Healthcare Providers & Services industry
Industry Median: 10.17
vs SAU:9600: 13.21
Qomel Co (SAU:9600) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Qomel Co Return-on-Tangible-Equity Related Terms
Qomel Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Qomel Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qomel Co Return-on-Tangible-Equity Competitor Comparison
For the Pharmaceutical Retailers subindustry, Qomel Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qomel Co Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Qomel Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Qomel Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 8.33% mean?
Qomel Co (SAU:9600) has a Return-on-Tangible-Equity of 8.33% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Qomel Co and its competitors. This is 71% below median its historical median of 29.21. Over the past decade, Qomel Co's Return-on-Tangible-Equity has ranged from 13.21 to 38.72. According to the industry distribution chart, Qomel Co ranks #252 out of 576 companies in the Healthcare Providers & Services industry, placing it in the top 43.7%.
Is Qomel Co's Return-on-Tangible-Equity too high?
Qomel Co's current Return-on-Tangible-Equity of 8.33% is 71% below median its 10-year median of 29.21. Over the past 10 years, this metric has ranged from a low of 13.21 to a high of 38.72. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.17. Qomel Co's value of 8.33% is 18.1% below this industry median. Based on the distribution chart, Qomel Co ranks #252 out of 576 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Qomel Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Qomel Co's Return-on-Tangible-Equity compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Qomel Co ranks #252 out of 576 companies for Return-on-Tangible-Equity. This puts Qomel Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.17. Qomel Co's value of 8.33% is 18.1% below this benchmark. Historically, Qomel Co's own Return-on-Tangible-Equity has ranged from 13.21 to 38.72 over the past decade. While the company's 10-year median is 29.21 vs. the industry median of 10.17, Qomel Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.17, based on 576 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qomel Co's current Return-on-Tangible-Equity of 8.33% is 18.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Qomel Co and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qomel Co's current Return-on-Tangible-Equity is 8.33%, which is 71% below median its own 10-year median of 29.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qomel Co stock overvalued right now?
Qomel Co (SAU:9600) has a current Return-on-Tangible-Equity of 8.33%. The current Return-on-Tangible-Equity is 8.33%, which is 71% below median its 10-year median of 29.21 and 18.1% below the Healthcare Providers & Services industry median of 10.17. Qomel Co's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Qomel Co (SAU:9600), the current Return-on-Tangible-Equity is 8.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Qomel Co is a Saudi Arabian-based healthcare company that provides high-quality medicines and innovative medical services whose core business focuses on institutional and government supply through a professional field force and an in-depth knowledge of the local business environment They offer services such as pharmaceutical and medical supplies.
23GF Score
Get the complete analysis for SAU:9600
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:9600 has been successfully added to your 
